Press Releases
Date picker
Category
Results per page
Kancera completes acquisition of the Fractalkine project for autoimmune diseases and cancer
Kancera AB (publ) has previously announced the Board's decision to execute the company's exclusive option to acquire the Fractalkine project from Acturum Real Estate AB after transfer of results and…
Kancera comments: Breakthrough for drug development targeting the Fractalkine system that controls immune cells and cancer cells
Blocking the Fractalkine system has been shown in clinical trials to have the desired effects in humans against intractable forms of autoimmune diseases. The results are in line with the…
INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December 31st 2016
Regulatory
THE PERIOD JANUARY - DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income…
Kancera provides operational update of the project portfolio
Kancera AB (publ) presents new information on - how the company's Fractalkine blocker prevents immune cells (monocytes) to infiltrate the nerves and spinal cord, which prevents nerve damage and enhanced…
Kancera appoints Joachim Forsgren as Chief Medical Officer
This is a translation from a swedish press release Stockholm dated 2016-12-23. Kancera AB (publ) today announced that Joachim Forsgren (MD, PhD) has been appointed Chief Medical Officer and will…
Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs
Kancera AB (publ) today reported that the drug candidate KAN0440567 quickly and effectively counteracts the kind of pain that results from chemotherapy and that often prevents effective treatment of cancer.…
Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016
Regulatory
The period January to September 2016 in brief R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m). Operating…
Kancera announces results from the ROR project in connection with a presentation on November 17th
In connection with a presentation at the Swedish Shareholders' Association on 17 November in Vimmerby, Kancera communicates new results in the ROR project. These results indicate that the company's ROR…
Kancera prepares for clinical development
Kancera AB (publ) announced today that Niclas Brynne has been appointed to lead Kancera's clinical development projects. He will be part of the management team and report directly to the…
Interim Report for Kancera AB (publ) Q2 2016 January 1 – June 30, 2016
Regulatory
As a consequence of the acquisition of the subsidiary Kancera Förvaltning AB on 2016-06-16, the present Interim Report, Q2 2016, is prepared in accordance with IAS 34 and related parts…